

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

JDH 京东健康

JD Health International Inc.

京东健康股份有限公司

(A company incorporated in the Cayman Islands with limited liability)

(Stock Code: 6618)

INSIDE INFORMATION

UNAUDITED UPDATE ON THE 2023 FIRST QUARTER

This announcement is issued by JD Health International Inc. (the “**Company**” or “**JD Health**”, and together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Business Update

- During the first quarter of 2023, our business maintained its robust growth momentum with revenue reaching RMB13,950 million, representing a year-over-year increase of 54.2%. As consumers increasingly associate JD Health with trust and reliability, our annual active user accounts increased to 159.7 million as of March 31, 2023, and our average daily consultation volume exceeded 400,000 during the first quarter of 2023.
- During the first quarter of 2023, JD Health signed strategic cooperation agreements for 2023 with global pharmaceutical and healthcare brands including H&H Group, Tongrentang Health, and Abbott. We also reached a strategic partnership with Zoetis Inc., a leading global animal healthcare company, to delve more deeply into the pet healthcare market through comprehensive cooperation and provide quality pet vaccines and medications to customers in China. Going forward, JD Health will further strengthen our supply chain capabilities, optimize and open up our ecosystem, and continue to promote our omnichannel initiative, with the goal of achieving quality growth together with our partners and merchants.

- In February 2023, JD Health upgraded its Rare Diseases Care Program to further expand drug coverage and continued to improve the capacity and accessibility of online medical services to serve a wider range of patients. As of March 2023, JD Health provided services to more than 200,000 patients with rare diseases across the country, including online healthcare and medication consultations, and offered a full range of Special Medical Purpose foods and products that have been approved in China. We have also reached a strategic cooperation arrangement with BO'AO Winhealth Rare Disease Medical Center and played a leading and exploratory role in promoting the accessibility of drugs and healthcare products for rare diseases, enabling patients with rare diseases to obtain products that have been marketed overseas but were not yet available in China.
- In the first quarter of 2023, the JD Health Partner Conference was held in Beijing. Building on the foundation of reliable and accessible online medical and healthcare services, JD Health is further exploring the application of internet and artificial intelligence technologies, and continues to build its internet hospital integrating medical services, continuing medical education and research support services. In terms of innovative technologies, JD Health's medical knowledge system has covered more than 1,000 common diseases and provided doctors with intelligent diagnosis and treatment supports, further enhancing the quality and efficiency of online medical services.

Unaudited Financial Information

The Company is pleased to announce the unaudited revenue and operating income of the Group for the three months ended March 31, 2023 together with comparative figures for the corresponding period of 2022:

	Three months ended		Change (%)
	March 31,		
	2023	2022	
	<i>RMB'000</i>	<i>RMB'000</i>	
	(Unaudited)	(Unaudited)	
Revenue	13,950,397	9,047,838	54.2
Operating income*	795,445	61,641	1,190.4
Non-IFRS operating income**	1,156,955	556,657	107.8

* Operating income consists of gross profit deducting fulfillment expenses, selling and marketing expenses, research and development expenses, general and administrative expenses, and impairment losses under expected credit loss model, net of reversal.

** We define "non-IFRS operating income" as operating income for the period, excluding share-based payment expenses for the period. We exclude this item because it is non-operating in nature, not indicative of our core operating results and business outlook, and it does not generate any cash outflows.

The above information is based on the board (the “**Board**”) of directors (the “**Directors**”) of the Company’s preliminary review of the internal data currently available and gathered by the Company only and is not intended to be a comprehensive statement of the Group’s financial result. The said information and data have not been audited or reviewed by the Company’s auditors and may be subject to change and adjustment.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
JD Health International Inc.
Mr. Enlin Jin
Executive Director

Hong Kong, May 11, 2023

As of the date of this announcement, the Board comprises Mr. Enlin Jin as the executive Director, Mr. Richard Qiangdong Liu and Mr. Qingqing Yi as non-executive Directors, and Ms. Ling Li, Dr. Jiyu Zhang, Mr. Xingyao Chen and Mr. Ying Wu as independent non-executive Directors.